Originally incorporated under the laws of the United Kingdom and Wales on February 11, 1998 as Bigboom plc, Tiziana Life Sciences Ltd is a biotechnology company focused on the discovery and development of novel molecules and related diagnostic agents to treat highly unmet medical needs in oncology and immunology. The lead product candidate for Tiziana Immunology is Foralumab (TZLS-401), which they believe is the only fully human anti-CD3 monoclonal antibody or mAb in clinical development. MAbs stand for single pure antibodies produced by monoclones and are an important class of human therapeutic agents for the treatment of cancer and autoimmune diseases. The main product candidate in the field of oncology is Milciclib (TZLS-201), which is an oral bioavailable small molecule broad-spectrum inhibitor that is influenced by cyclin-dependent kinases or CDKs and Src family kinases.